Journal of Enzyme Inhibition and Medicinal Chemistry (Jan 2020)

Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors

  • Thomas S. Corrigan,
  • Leilani M. Lotti Diaz,
  • Sarah E. Border,
  • Steven C. Ratigan,
  • Kayla Q. Kasper,
  • Daniel Sojka,
  • Pavla Fajtova,
  • Conor R. Caffrey,
  • Guy S. Salvesen,
  • Craig A. McElroy,
  • Christopher M. Hadad,
  • Özlem Doğan Ekici

DOI
https://doi.org/10.1080/14756366.2020.1781107
Journal volume & issue
Vol. 35, no. 1
pp. 1387 – 1402

Abstract

Read online

Aza-peptide aldehydes and ketones are a new class of reversible protease inhibitors that are specific for the proteasome and clan CD cysteine proteases. We designed and synthesised aza-Leu derivatives that were specific for the chymotrypsin-like active site of the proteasome, aza-Asp derivatives that were effective inhibitors of caspases-3 and -6, and aza-Asn derivatives that inhibited S. mansoni and I. ricinus legumains. The crystal structure of caspase-3 in complex with our caspase-specific aza-peptide methyl ketone inhibitor with an aza-Asp residue at P1 revealed a covalent linkage between the inhibitor carbonyl carbon and the active site cysteinyl sulphur. Aza-peptide aldehydes and ketones showed no cross-reactivity towards cathepsin B or chymotrypsin. The initial in vitro selectivity of these inhibitors makes them suitable candidates for further development into therapeutic agents to potentially treat multiple myeloma, neurodegenerative diseases, and parasitic infections.

Keywords